Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491958 | 0.85 | KMT2A (0.54) | MEN1KMT2ALMNAMAPK1POLB | |
| SCHEMBL3488988 | 0.84 | MEN1 (0.50) | MEN1KMT2AMAPK1POLBKDM4E | |
| SCHEMBL3490784 | 0.81 | HPGD (0.47) | MEN1KMT2ALMNAMAPK1POLB | |
| SCHEMBL3490963 | 0.81 | KMT2A (0.50) | MEN1KMT2ALMNAPOLBKDM4E | |
| SCHEMBL9210947 | 0.81 | SMN1; SMN2 (0.50) | LMNAMAPK1HTTMAPTNR3C1 | |
| SCHEMBL3490906 | 0.80 | CA2 (0.53) | MEN1KMT2ANR3C1NR3C2PGR | |
| SCHEMBL3490747 | 0.79 | NPC1 (0.57) | MEN1KMT2ALMNAPOLBHTT | |
| SCHEMBL9272679 | 0.79 | NR3C1 (0.48) | MEN1KMT2ALMNAMAPTNR3C1 | |
| SCHEMBL3491178 | 0.78 | LMNA (0.52) | MEN1KMT2ALMNAPOLBNR3C1 | |
| SCHEMBL3490641 | 0.78 | LMNA (0.52) | LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-0636124-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021170-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | MEN1 4200/4885KMT2A 4557/4885LMNA 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.